O
NBIX icon

OppenheimerFunds’s Neurocrine Biosciences NBIX Stock Holding History

OppenheimerFunds’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$9.21M Sell
104,484
-494,699
-83% -$41.3M 0.01% 681
2018
Q4 		$42.8M Sell
599,183
-233,036
-28% -$22.3M 0.06% 312
2018
Q3 		$102M Sell
832,219
-19,234
-2% -$2.18M 0.12% 187
2018
Q2 		$83.6M Buy
851,453
+16,455
+2% +$1.47M 0.1% 224
2018
Q1 		$69.2M Buy
834,998
+29,751
+4% +$2.51M 0.09% 253
2017
Q4 		$62.5M Buy
805,247
+226,127
+39% +$15.4M 0.08% 269
2017
Q3 		$35.5M Sell
579,120
-310
-0.1% -$16.4K 0.04% 392
2017
Q2 		$26.7M Buy
579,430
+84,660
+17% +$4.11M 0.03% 462
2017
Q1 		$21.4M Sell
494,770
-406,768
-45% -$17.4M 0.03% 558
2016
Q4 		$34.9M Sell
901,538
-101,010
-10% -$4.57M 0.04% 405
2016
Q3 		$50.8M Buy
1,002,548
+170,680
+21% +$8.5M 0.06% 319
2016
Q2 		$37.8M Buy
831,868
+309,308
+59% +$14.2M 0.05% 384
2016
Q1 		$20.7M Buy
522,560
+222,222
+74% +$8.82M 0.03% 555
2015
Q4 		$17M Buy
300,338
+34,818
+13% +$1.77M 0.02% 622
2015
Q3 		$10.6M Sell
265,520
-82,260
-24% -$3.98M 0.01% 707
2015
Q2 		$16.6M Buy
347,780
+164,680
+90% +$6.98M 0.02% 632
2015
Q1 		$7.27M Buy
+183,100
New +$6.55M 0.01% 802

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OppenheimerFunds's NBIX Position: Q1 2019 in Review

OppenheimerFunds reduced its Neurocrine Biosciences (NBIX) stake by 83% in Q1 2019, selling an estimated $41.3M and leaving 104,484 shares worth $9.21M. The position accounts for 0.01% of the portfolio, ranked #681.

OppenheimerFunds first reported a position in NBIX in Q1 2015 and has held it in 17 quarters since. The position peaked at $102M in Q3 2018. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • OppenheimerFunds held 104,484 shares of Neurocrine Biosciences worth $9.21M as of Q1 2019.
  • OppenheimerFunds sold 494,699 Neurocrine Biosciences shares in Q1 2019, an estimated $41.3M.
  • Neurocrine Biosciences made up 0.01% of OppenheimerFunds's portfolio in Q1 2019, its #681 holding.
  • OppenheimerFunds first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 17 quarters since.
  • OppenheimerFunds's Neurocrine Biosciences position peaked at $102M in Q3 2018.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.